

Applicants: Ron S. Israeli, et al.

Serial No.: 08/466,381

Filed : June 6, 1995

Page 3

the paper and computer readable copies of the Sequence Listing as well as the statement.

In response, applicants have amended their specification to define the segments shown in Figure 15B as portions or "residues" of SEQ ID NO:2. Support for this amendment is found in Figure 15B which defines the position of the segments and in Figure 14, panels 4-8 as well as SEQ ID NO:2 which illustrate the position of the subject segments in the PSM antigen. No new matter is added with this amendment. Since this amendment defines the segments in Figure 15B as residues of SEQ ID NO: 2, i.e., a pre-existing SEQ ID NO., no substitute paper or computer readable copies of the Sequence Listing or statement are provided in accordance with the statement noted above to that effect in the Communication.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone at the number provided below.

Applicants: Ron S. Israeli, et al.

Serial No.: 08/466,381

Filed : June 6, 1995

Page 4

No fee is deemed necessary in connection with the filing of this response. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125

Respectfully submitted,

Mark A. Farley

John P. White
Registration No. 28,678
Mark A. Farley
Registration No. 33,170
Attorneys for Applicant(s)
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Mark A. Farley 11/18/02
John P. White Date
Reg. No. 28,678
Mark A. Farley
Reg. No. 33,170